Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $9.52 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
• Signet shares jump on Q2 profit beat, raised annual guidance